Coxsackievirus

Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Retrieved on: 
Friday, March 24, 2023

We plan to submit an IND with the FDA for ONCR-021 in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus.

Key Points: 
  • We plan to submit an IND with the FDA for ONCR-021 in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus.
  • Research and development expenses for the quarter ended December 31, 2022 were $15.7 million compared to $14.3 million for the corresponding quarter in 2021.
  • General and administrative expenses for the quarter ended December 31, 2022 were $5.1 million compared to $5.6 million for the corresponding quarter in 2021.
  • Oncorus expects its cash, cash equivalents and investments to fund its capital expenditures and operating expenses into early 2024.

Oncorus Reports First Quarter 2021 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, May 4, 2021

We also anticipate nominating our first two synthetic viral RNA (vRNA) immunotherapy candidates in the first half of 2021.

Key Points: 
  • We also anticipate nominating our first two synthetic viral RNA (vRNA) immunotherapy candidates in the first half of 2021.
  • These candidates are comprised of vRNA coding for oncolytic viruses encapsulated within lipid nanoparticles, or LNPs \xe2\x80\x93 proprietary technologies developed by the Oncorus team.
  • Oncorus continues to advance its lead synthetic, IV administered vRNA immunotherapy programs based on the Coxsackievirus A21 (CVA21) and the Seneca Valley Virus (SVV).
  • In January 2021, Oncorus announced the signing of a 15-year lease to build a state-of-the-art, 88,000 square foot GMP viral immunotherapy clinical manufacturing facility in Andover, Mass.

Cancer-Killing Virus Therapy Shows Promise Against Inoperable Skin Cancers

Retrieved on: 
Friday, April 9, 2021

The drug combination is among the first, researchers say, to demonstrate the potential value of a live common cold virus, a coxsackievirus, to infect and kill cancer cells.

Key Points: 
  • The drug combination is among the first, researchers say, to demonstrate the potential value of a live common cold virus, a coxsackievirus, to infect and kill cancer cells.
  • Currently, such immunotherapies are only effective in shrinking melanoma tumors in just over a third of patients who receive them.
  • The new study results showed that injections of experimental coxsackievirus drug V937, along with pembrolizumab, an immunotherapy drug known as pembro or Keytruda, was well tolerated.
  • Moreover, the combined treatment shrank melanoma tumors in nearly half (47 percent) of 36 men and women who received the therapy every few weeks for at least two years.

Cancer-Killing Virus Therapy Shows Promise Against Inoperable Skin Cancers

Retrieved on: 
Friday, April 9, 2021

The drug combination is among the first, researchers say, to demonstrate the potential value of a live common cold virus, a coxsackievirus, to infect and kill cancer cells.

Key Points: 
  • The drug combination is among the first, researchers say, to demonstrate the potential value of a live common cold virus, a coxsackievirus, to infect and kill cancer cells.
  • Currently, such immunotherapies are only effective in shrinking melanoma tumors in just over a third of patients who receive them.
  • The new study results showed that injections of experimental coxsackievirus drug V937, along with pembrolizumab, an immunotherapy drug known as pembro or Keytruda, was well tolerated.
  • Moreover, the combined treatment shrank melanoma tumors in nearly half (47 percent) of 36 men and women who received the therapy every few weeks for at least two years.

Provention Bio Receives Notice of Allowance from United States Patent and Trademark Office for Patent on Multi-Strain Coxsackievirus B Vaccine for Preventing or Treating Type 1 Diabetes (T1D)

Retrieved on: 
Monday, January 28, 2019

The patent application covers methods of use involving the development of a coxsackievirus B (CVB) vaccine for the prevention and/or treatment of type 1 diabetes (T1D).

Key Points: 
  • The patent application covers methods of use involving the development of a coxsackievirus B (CVB) vaccine for the prevention and/or treatment of type 1 diabetes (T1D).
  • Provention Bio is developing PRV-101 as a vaccine for acute coxsackie virus infection and potentially as the first-ever vaccine designed to prevent T1D.
  • Epidemiological and experimental studies indicate that approximately half of all T1D cases could be triggered by a CVB infection in early childhood.
  • There area number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.